Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
Rang în acțiuni #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Preț acțiune
$1.51
Ultima sincronizare: 2024-08-26
Capitalizare de piață
$1.12M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Agile Therapeutics, Inc. (AGRX)

Categorie

Raport P/B pentru Agile Therapeutics, Inc. (AGRX)
Raport P/B la data de August 2026 TTM: -0.20
Conform celor mai recente rapoarte financiare și prețului acțiunilor Agile Therapeutics, Inc., raportul P/B actual (TTM) este -0.20. La sfârșitul anului 2022, compania avea un P/B de -0.88.
Istoricul raportului P/B pentru Agile Therapeutics, Inc. din 2012 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
2026 (TTM) -0.20 -23.23%
2023 -0.26 -70.87%
2022 -0.88 -792.80%
2021 0.13 -97.41%
2020 4.93 82.38%
2019 2.70 175.75%
2018 0.98 -57.24%
2017 2.29 -39.87%
2016 3.81 -47.25%
2015 7.22 271.82%
2014 1.94 -377.53%
2013 -0.70 -17.96%
2012 -0.85 0.00%
Raport P/B pentru companii similare sau competitoare